Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2016-05-10 Interim / Quarterly Rep…
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
20160510_PR_Q1 update_Final _FR.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a quarterly activity report from Bone Therapeutics for Q1 2016. It contains substantive financial data (cash position, operating loss, cash consumption) and detailed operational updates regarding clinical trials. It is not merely an announcement of a report, but the report itself, fitting the definition of an Interim/Quarterly Report (IR). Q1 2016
2016-05-10 French
20160510_PR_Q1 update_Final _NL.pdf
Earnings Release Classification · 98% confidence The document is titled "Bone Therapeutics geeft Business Update voor het Eerste Kwartaal van 2016" (Bone Therapeutics provides Business Update for the First Quarter of 2016). It details operational highlights, financial highlights (cash position, operating loss) for the first quarter, and future outlook. This structure—a summary of recent performance and financial metrics for a specific reporting period (Q1 2016)—is characteristic of an Earnings Release (ER) or an Interim/Quarterly Report (IR). Since it focuses on key highlights and financial summaries rather than being a comprehensive, detailed financial statement (which would lean towards IR), and it is explicitly framed as a 'Business Update' following the period end, it best fits the Earnings Release (ER) category. The length (over 10,000 characters) confirms it is more than just a brief announcement of a report. Q1 2016
2016-05-10 Dutch
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated May 3, 2016, announcing that Bone Therapeutics has completed recruitment for its ALLOB® Phase IIA spinal fusion study and is extending the trial. It details clinical progress, safety, and expected timelines for efficacy data. This type of announcement, focusing on clinical trial milestones and operational updates, is characteristic of an Earnings Release (ER) if it were tied to a quarterly report, or more generally, a press release containing material operational news. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, and it provides key operational highlights (trial completion, extension plans), it best fits the 'Earnings Release' category (ER) which often encompasses major operational updates released outside of formal quarterly filings, or the general 'Regulatory Filings' (RNS) if it were purely regulatory. Given the content focuses on trial progress and future data reporting, it functions as a significant operational update, often grouped with ERs or as a general announcement. However, since it is a press release announcing operational progress rather than formal financial results, and it doesn't fit the other specific categories, RNS (Regulatory Filings) is the most appropriate fallback for a general, material press release that isn't a formal financial report or a specific event announcement like DIV or DIRS. Upon review, ER (Earnings Release) is often used for press releases announcing key operational milestones alongside or instead of financial results. Given the focus on trial progress and future data reporting, it is a significant corporate update. Since it is not a formal financial report, RNS is the safest general classification for a material press release not covered elsewhere. Let's re-evaluate against ER: ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is an announcement about a clinical trial milestone, not financial results. Therefore, RNS (Regulatory Filings/General Announcement) is the best fit as it is a material, non-financial regulatory announcement.
2016-05-03 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Legal Proceedings Report Classification · 99% confidence The document is a press release dated May 3, 2016, announcing the completion of patient recruitment for a Phase IIA clinical study regarding spinal fusion using the ALLOB® cell therapy product. It details the study progress, plans for an extension, and upcoming data release timelines. This type of announcement, focusing on clinical trial milestones and operational updates rather than comprehensive financial results (like a 10-K or IR) or formal voting results, is characteristic of an Earnings Release (ER) or a general corporate update. Since it announces key operational and clinical progress, it fits best under the 'Earnings Release' category, which often includes operational highlights alongside or instead of preliminary financial figures, or it could be classified as a Regulatory Filing (RNS) if it were purely regulatory. Given the structure and focus on study progress and future data communication, it strongly resembles an Earnings Release announcement, even if financial data is minimal or absent, as it communicates key performance indicators (KPIs) for the period/program. However, since it is primarily a clinical trial update and not explicitly an 'Earnings Release' announcing financial results for a period, the most appropriate general category for a significant, non-financial operational update that isn't a specific report announcement is often the general Regulatory Filing category (RNS) or, if it contains management commentary on performance, ER. Given the context of clinical trial progress announcements, which are often bundled with ERs, I will lean towards ER as it communicates key operational 'results' for the period. If the document were shorter and just linking to a report, it would be RPA/RNS. Since it is a detailed announcement of a milestone, ER is plausible, but RNS is the safest fallback for non-standard announcements. Let's re-evaluate the definitions. It is not a 10-K, AR, CT, DIV, or DEF 14A. It is an announcement of a clinical milestone. This is often released via RNS (Regulatory News Service) or as part of an ER. Since it is a detailed announcement of a specific operational event (study recruitment completion), and not a formal financial report, RNS is the most accurate general regulatory category for such specific, non-standard updates.
2016-05-03 French
Bone Therapeutics completes recruitment of its ALLOB® Phase IIA spinal fusion study
Regulatory Filings Classification · 95% confidence The document is a press release dated May 3, 2016, announcing that Bone Therapeutics has completed recruitment for its ALLOB® Phase IIA spinal fusion study and is extending the trial. It details clinical progress, safety, and expected timelines for efficacy data. This type of announcement, focusing on clinical trial milestones and operational updates, is characteristic of an Earnings Release (ER) if it were tied to a quarterly report, or more generally, a press release containing material operational news. Since it is not a full financial report (10-K, IR), a transcript (CT), or a specific regulatory filing like DIRS or DIV, and it provides key operational highlights (trial completion, extension plans), it best fits the 'Earnings Release' category (ER) which often encompasses major operational updates released outside of formal quarterly filings, or the general 'Regulatory Filings' (RNS) if it were purely regulatory. Given the content focuses on trial progress and future data reporting, it functions as a significant operational update, often grouped with ERs or as a general announcement. However, since it is a press release announcing operational progress rather than formal financial results, and it doesn't fit the other specific categories, RNS (Regulatory Filings) is the most appropriate fallback for a general, material press release that isn't a formal financial report or a specific event announcement like DIV or DIRS. Upon review, ER (Earnings Release) is often used for press releases announcing key operational milestones alongside or instead of financial results. Given the focus on trial progress and future data reporting, it is a significant corporate update. Since it is not a formal financial report, RNS is the safest general classification for a material press release not covered elsewhere. Let's re-evaluate against ER: ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is an announcement about a clinical trial milestone, not financial results. Therefore, RNS (Regulatory Filings/General Announcement) is the best fit as it is a material, non-financial regulatory announcement.
2016-05-03 English
Bone Therapeutics annonce la fin du recrutement de l’étude de Phase IIA dans la fusion vertébrale
Regulatory Filings Classification · 95% confidence The document is a press release dated May 3, 2016, announcing the completion of patient recruitment for a Phase IIA clinical study regarding spinal fusion using the ALLOB® cell therapy product. It details the study progress, plans for an extension, and upcoming data release timelines. This type of announcement, focusing on clinical trial milestones and operational updates rather than comprehensive financial results (like a 10-K or IR) or formal voting results, is characteristic of an Earnings Release (ER) or a general corporate update. Since it announces key operational and clinical progress, it fits best under the 'Earnings Release' category, which often includes operational highlights alongside or instead of preliminary financial figures, or it could be classified as a Regulatory Filing (RNS) if it were purely regulatory. Given the structure and focus on study progress and future data communication, it strongly resembles an Earnings Release announcement, even if financial data is minimal or absent, as it communicates key performance indicators (KPIs) for the period/program. However, since it is primarily a clinical trial update and not explicitly an 'Earnings Release' announcing financial results for a period, the most appropriate general category for a significant, non-financial operational update that isn't a specific report announcement is often the general Regulatory Filing category (RNS) or, if it contains management commentary on performance, ER. Given the context of clinical trial progress announcements, which are often bundled with ERs, I will lean towards ER as it communicates key operational 'results' for the period. If the document were shorter and just linking to a report, it would be RPA/RNS. Since it is a detailed announcement of a milestone, ER is plausible, but RNS is the safest fallback for non-standard announcements. Let's re-evaluate the definitions. It is not a 10-K, AR, CT, DIV, or DEF 14A. It is an announcement of a clinical milestone. This is often released via RNS (Regulatory News Service) or as part of an ER. Since it is a detailed announcement of a specific operational event (study recruitment completion), and not a formal financial report, RNS is the most accurate general regulatory category for such specific, non-standard updates.
2016-05-03 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.